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Aim To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective
comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial,
testing the hypothesis that the strategy of simultaneously blocking the renin–angiotensin–aldosterone system and
augmenting natriuretic peptides with LCZ696 200mg b.i.d. is superior to enalapril 10mg b.i.d. in reducing mortality
and morbidity in patients with heart failure and reduced ejection fraction.
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Methods Key demographic, clinical and laboratory findings, along with baseline treatment, are reported and compared with
those of patients in the treatment arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) and more
contemporary drug and device trials in heart failure and reduced ejection fraction.
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Results The mean age of the 8442 patients in PARADIGM-HF is 64 (SD 11) years and 78% are male, which is similar
to SOLVD-T and more recent trials. Despite extensive background therapy with beta-blockers (93% patients)
and mineralocorticoid receptor antagonists (60%), patients in PARADIGM-HF have persisting symptoms and signs,
reduced health related quality of life, a low LVEF (mean 29± SD 6%) and elevated N-terminal-proB type-natriuretic
peptide levels (median 1608 inter-quartile range 886–3221 pg/mL).
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Conclusion PARADIGM-HF will determine whether LCZ696 is more beneficial than enalapril when added to other
disease-modifying therapies and if further augmentation of endogenous natriuretic peptides will reduce morbidity
and mortality in heart failure and reduced ejection fraction.
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Introduction
The role of endogenous natriuretic peptides in protecting against
sodium and volume overload is well recognized and this family of
peptides is believed to have an range of other beneficial cardiac,
vascular, and renal actions.1,2 More recently, it has been suggested
that natriuretic peptides also have favourable metabolic actions,
including improvement of glucose tolerance and reduction in
adipocyte growth.1,2
Endogenous concentrations of natriuretic peptides can be
increased through inhibition of the enzyme responsible for their
degradation [i.e. neutral endopeptidase (NEP), also known as
neprilysin].2,3 There have been several attempts to determine
whether inhibition of NEP is of benefit in patients with cardiovas-
cular disease.2,4–6
Because NEP also degrades angiotensin II, NEP inhibition
must be combined with an angiotensin converting enzyme (ACE)
inhibitor or angiotensin receptor blocker (ARB).2,3,7 The former
approach was tested with omapatrilat, but blockade of both
NEP and ACE (and probably a third enzyme, aminopeptidase P)
resulted in an unacceptable risk of angioedema because each of
these enzymes is also involved in the breakdown of bradykinin.3,7,8
The angiotensin receptor blocker-neprilysin inhibitor (ARNi)
LCZ696 provides an alternative approach to simultaneously
blocking the renin–angiotensin–aldosterone system (RAAS) and
augmenting endogenous natriuretic peptides, without increasing
bradykinin excessively.3,7,9
The Prospective comparison of ARNi with ACEi to Determine
Impact on Global Mortality and morbidity in Heart Failure trial
(PARADIGM-HF) is testing the hypothesis that LCZ696 200mg
b.i.d is superior to enalapril 10mg bid is reducing mortality and
morbidity in patients with heart failure and reduced ejection
fraction (HF-REF).7 Enalapril was chosen as the comparator as
the only ACE inhibitor shown to reduce mortality in a broad
spectrum of patients with HF-REF in the treatment arm of the
Studies Of Left Ventricular Dysfunction (SOLVD-T).9 A 200mg
b.i.d. dose of LCZ696 was selected because it provides equivalent
exposure as valsartan 160mg b.i.d. (the target dose in heart failure
and presumed similar RAAS blockade to enalapril 10mg b.i.d.),
as well as near-complete NEP inhibition. Here we describe the
baseline characteristics and treatment of the more than 8400
patients randomized in PARADIGM-HF, comparing these with
both SOLVD-T and more contemporary drug and device trials in
HF-REF.
Methods
As described previously, PARADIGM-HF is a randomized, double-blind,
parallel group, active-controlled, two-arm, event-driven trial comparing
the long-term efficacy and safety of enalapril and LCZ696 in patients
with chronic symptomatic HF-REF.7 The key entry criteria are shown
in Table 1.
There are four phases in PARADIGM-HF, the rationale for which has
been explained previously: (i) screening, (ii) single-blind enalapril run-in,
(iii) single-blind LCZ696 run-in, and (iv) randomized, double-blind,
treatment.7 At the screening visit, patient eligibility was assessed ..
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.. including left ventricular ejection fraction (LVEF), New York Heart
Association (NYHA) class, BNP or N-terminal pro-brain natriuretic
peptide (NT-proBNP), serum potassium, and estimated glomerular
filtration rate (eGFR), measured in a central laboratory. Eligible
patients then entered a single-blind enalapril run-in followed by
a single-blind LCZ696 run-in. Patients tolerating both enalapril
10mg b.i.d. and LCZ696 200mg b.i.d. were randomized in a 1 :1
ratio to double-blind treatment with either enalapril 10mg b.i.d.
or LCZ696 200mg b.i.d. Tolerability for randomization was deter-
mined as: potassium ≤5.4mmol/L; eGFR ≥30mL/min.1.73m2 and
no decrease in eGFR of >25% (later amended to >35%) from the
screening visit; no symptomatic hypotension, no postural symptoms
and systolic blood pressure (BP) ≥95mmHg; no other adverse events
precluding continuation in the trial, according to the investigator’s
judgement.
The primary objective of the trial is to evaluate the effect of LCZ696
200mg b.i.d. compared with enalapril 10mg b.i.d., in addition to con-
ventional heart failure treatment, in delaying time to first occurrence
of either cardiovascular (CV) death or hospitalization owing to heart
failure. Both components of the composite will also be analysed sep-
arately, in accordance with regulatory guidance, and these additional
analyses will be considered as part of the primary endpoint and not as
secondary outcomes. The trial has 80% power to detect a 15% reduc-
tion in cardiovascular mortality once 1229 of these events accrue.
Secondary objectives are to test whether LCZ696, compared with
enalapril, is superior: (i) in improving the Kansas City Cardiomyopa-
thy Questionnaire (KCCQ) clinical summary score for heart failure
symptoms and physical limitations at 8months; (ii) in delaying the
time to all-cause mortality; (iii) in delaying time to new-onset atrial
fibrillation; and (iv) in delaying decline in renal function. There are
also a number of exploratory objectives. The statistical considerations
related to PARADIGM-HF have been described in detail elsewhere.7
Briefly, the sample size is based upon CV mortality with 1229 deaths
required to give 80% power to detect a relative risk reduction of 15%
in the LCZ696 group, compared with the enalapril group, although
the trial will continue until at least 2410 patients have experienced
CV death, or hospitalization owing to heart failure (meaning it should
have >97% power to detect a relative risk reduction of 15% in this
primary composite outcome). Hence, PARADIGM-HF was designed
as both a mortality trial and a mortality/morbidity trial and the Data
Monitoring Committee will only consider early termination at its
pre-planned interim analyses if both the primary composite outcome
and CV mortality are reduced, in accordance with the pre-specified
boundaries.
The present report describes an analysis of the baseline character-
istics of the 8442 patients randomized in PARADIGM-HF (this number
includes 6 patients found to be incorrectly randomized who had
violated the inclusion criteria and who were removed from the trial
before receiving study-drug). As described above, the reference com-
parator in PARADIGM-HF is enalapril 10mg b.i.d., which was chosen
because of the seminal findings of the Treatment Arm of the Studies
Of Left Ventricular Dysfunction (SOLVD-T).9 For this reason we have
compared the characteristics of patients in PARADIGM-HF with those
in SOLVD-T. The baseline characteristics of the Candesartan in Heart
failure: Assessment of Reduction in Mortality and morbidity-Added
(CHARM-Added) trial are also shown as this was used to estimate
the rate of the primary outcome in PARADIGM-HF.10 Furthermore,
to better understand the patients enrolled in PARADIGM-HF in
a more contemporary setting, we have compared the patients in
PARADIGM-HF with those in a range of recent trials in HF-REF that
have reported comparable data.11–25
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
PARADIGM-HF baseline characteristics 819
Ta
bl
e
1
D
es
ig
n
o
fS
O
LV
D
-T
,P
A
R
A
D
IG
M
-H
F
an
d
o
th
er
,r
ec
en
t,
la
rg
e
ra
nd
o
m
iz
ed
co
nt
ro
lle
d
tr
ia
ls
in
he
ar
t
fa
ilu
re
an
d
re
du
ce
d
ej
ec
ti
o
n
fr
ac
ti
o
n
(H
F
-R
E
F
)
S
O
LV
D
-T
i ,
N
=
25
69
C
H
A
R
M
-A
dd
ed
10
,
N
=
25
48
H
E
A
A
L
11
,
N
=
38
34
R
A
F
T
12
,
N
=
17
98
S
H
IF
T
13
,
N
=
65
05
E
M
P
H
A
S
IS
-H
F
a ,
N
=
27
37
PA
R
A
D
IG
M
-H
F
g ,
N
=
84
42
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
In
cl
us
io
n
cr
ite
ri
a
A
ge
(y
ea
rs
)
21
–
80
≥
18
≥
18
≥
18
≥
18
≥
55
≥
18
N
Y
H
A
cl
as
s
II
–
IV
II
–
IV
II
–
IV
II
–
III
d
II
–
IV
II
II
–
IV
LV
EF
(%
)
≤
35
%
≤
40
%
≤
40
%
≤
30
%
≤
35
%
≤
30
%
f
≤
40
%
g
H
F
ho
sp
ita
liz
at
io
n
N
o
Ye
sb
N
o
N
o
Ye
se
Ye
sb
Ye
sh
O
th
er
–
–
–
Si
nu
s
rh
yt
hm
Q
R
Sd
≥
12
0
m
s
Si
nu
s
rh
yt
hm
ra
te
≥
70
bp
m
–
BN
P
15
0
pg
/m
l(
N
T
-p
ro
BN
P
≥
60
0
pg
/m
L)
C
re
at
in
in
e,
μm
ol
/L
≤
22
0a
<
26
5
≤
22
0
–
≤
22
0
–
–
eG
FR
,
–
–
–
–
–
≥
30
≥
30
m
L/
m
in
.1
.7
3
m
b
–
–
≥
90
–
≥
85
≥
85
≥
95
Sy
st
ol
ic
bl
oo
d
pr
es
su
re
,m
m
H
g
<
5.
5a
<
5.
5
≤
5.
7
–
–
<
5.
0
≤
5.
4
Po
ta
ss
iu
m
,m
m
ol
/L
R
un
-in
Pl
ac
eb
o/
co
nt
ro
l
Ye
s
N
o
N
o
N
o
Ye
s
N
o
Ye
s
A
ct
iv
e
Ye
s
N
o
Ye
sc
N
o
N
o
N
o
Ye
s
Ba
se
lin
e
tr
ea
tm
en
t
–
Be
ta
-b
lo
ck
er
Be
ta
-b
lo
ck
er
Be
ta
-b
lo
ck
er
Be
ta
-b
lo
ck
er
Be
ta
-b
lo
ck
er
Be
ta
-b
lo
ck
er
A
C
Ei
A
C
Ei
or
A
R
B
A
C
Ei
or
A
R
B
A
C
Ei
or
A
R
B
M
R
A
as
in
di
ca
te
d
M
R
A
as
in
di
ca
te
d
M
R
A
as
in
di
ca
te
d
M
R
A
as
in
di
ca
te
d
C
om
pa
ri
so
n
Pl
ac
eb
o
Pl
ac
eb
o
Lo
sa
rt
an
50
m
g
q.
d.
IC
D
Pl
ac
eb
o
Pl
ac
eb
o
En
al
ap
ri
l1
0
m
g
b.
i.d
.
En
al
ap
ri
l1
0
m
g
b.
i.d
.
C
an
de
sa
rt
an
32
m
g
q.
d.
Lo
sa
rt
an
15
0
m
g
q.
d.
C
RT
–
IC
D
Iv
ab
ra
di
ne
7.
5
m
g
b.
i.d
.
Ep
le
re
on
on
e
50
m
g
q.
d.
LC
Z
69
6
20
0
m
g
b.
i.d
.
R
ec
ru
itm
en
t
pe
ri
od
19
86
–
19
89
19
99
–
20
01
20
01
–
20
05
20
03
–
20
09
20
06
–
20
09
20
06
–
20
10
20
09
–
20
12
i
SO
LV
D
-T
,S
tu
di
es
of
Le
ft
Ve
nt
ri
cu
la
r
D
ys
fu
nc
tio
n
Tr
ea
tm
en
t
tr
ia
l;
C
H
A
R
M
-A
dd
ed
,C
an
de
sa
rt
an
in
H
ea
rt
fa
ilu
re
:A
ss
es
sm
en
t
of
R
ed
uc
tio
n
in
M
or
ta
lit
y
an
d
m
or
bi
di
ty
(C
H
A
R
M
)-
A
dd
ed
tr
ia
l;
H
EA
A
L,
H
ea
rt
fa
ilu
re
En
dp
oi
nt
ev
al
ua
tio
n
of
A
ng
io
te
ns
in
II
A
nt
ag
on
is
tL
os
ar
ta
n;
R
A
FT
,R
es
yn
ch
ro
ni
za
tio
n/
D
efi
br
ill
at
io
n
fo
r
A
m
bu
la
to
ry
H
ea
rt
Fa
ilu
re
Tr
ia
l;
SH
IF
T,
Sy
st
ol
ic
H
ea
rt
Fa
ilu
re
Tr
ea
tm
en
tw
ith
th
e
I f
In
hi
bi
to
r
Iv
ab
ra
di
ne
Tr
ia
l;
EM
PH
A
SI
S-
H
F,
Ep
le
re
no
ne
in
M
ild
Pa
tie
nt
s
H
os
pi
ta
liz
at
io
n
A
nd
Su
rv
iv
al
st
ud
y
in
H
ea
rt
Fa
ilu
re
;P
A
R
A
D
IG
M
-H
F,
Pr
os
pe
ct
iv
e
co
m
pa
ri
so
n
of
A
R
N
i(
an
gi
ot
en
si
n
re
ce
pt
or
ne
pr
ily
si
n
in
hi
bi
to
r)
w
ith
A
C
Ei
(a
ng
io
te
ns
in
-c
on
ve
rt
in
g
en
zy
m
e
in
hi
bi
to
r)
to
D
et
er
m
in
e
Im
pa
ct
on
G
lo
ba
l
M
or
ta
lit
y
an
d
m
or
bi
di
ty
in
H
ea
rt
Fa
ilu
re
tr
ia
l.
H
F,
he
ar
t
fa
ilu
re
;N
Y
H
A
,N
ew
Yo
rk
H
ea
rt
A
ss
oc
ia
tio
n
fu
nc
tio
na
lc
la
ss
;L
V
EF
,l
ef
t
ve
nt
ri
cu
la
r
ej
ec
tio
n
fr
ac
tio
n;
eG
FR
,e
st
im
at
ed
gl
om
er
ul
ar
fil
tr
at
io
n
ra
te
.
a S
O
LV
D
Pr
ot
oc
ol
st
at
es
a
cr
ea
tin
in
e
>
22
0
𝛍m
ol
/L
at
ba
se
lin
e
is
an
ex
cl
us
io
n
al
th
ou
gh
re
su
lts
m
an
us
cr
ip
t
st
at
es
>
17
7
𝛍m
ol
/L
.D
ur
in
g
ru
n-
in
pa
tie
nt
s
w
er
e
to
be
ex
cl
ud
ed
if
cr
ea
tin
e
in
cr
ea
se
d
by
88
.4
𝛍m
ol
/L
or
to
35
4
𝛍m
ol
/L
,
po
ta
ss
iu
m
in
cr
ea
se
d
to
5.
5
m
m
ol
or
gr
ea
te
r
or
th
e
pa
tie
nt
de
ve
lo
pe
d
sy
m
pt
om
at
ic
hy
po
te
ns
io
n.
b
in
C
H
A
R
M
-A
dd
ed
,c
ar
di
ac
ho
sp
ita
lis
at
io
n
w
ith
in
6
m
on
th
s
if
N
Y
H
A
cl
as
s
II;
in
EM
PH
A
SI
S-
H
F
ca
rd
io
va
sc
ul
ar
ho
sp
ita
liz
at
io
n
w
ith
in
6
m
on
th
s
(o
r
BN
P
≥
25
0
pg
/m
lo
r
N
T
pr
oB
N
P
≥
50
0
pg
/m
L
in
m
en
an
d
75
0
pg
/m
L
in
w
om
en
).
c o
pt
io
na
li
n
pa
tie
nt
s
al
re
ad
y
ta
ki
ng
an
A
R
B.
d
N
Y
H
A
cl
as
s
III
ex
cl
ud
ed
af
te
r
20
06
.
e w
ith
in
12
m
on
th
s.
f ≥
30
–
35
%
if
Q
R
S
du
ra
tio
n
>
13
0
m
s.
g c
ha
ng
ed
to
≤
35
%
D
ec
em
be
r
20
10
.
h
an
d
BN
P
≥
10
0
pg
/m
L
(o
r
N
T
-p
ro
BN
P
≥
40
0
pg
/m
L)
or
BN
P
≥
15
0
pg
/m
L
(N
T
pr
oB
N
P
≥
60
0
pg
/m
L)
if
no
he
ar
t
fa
ilu
re
ho
sp
ita
liz
at
io
n
w
ith
in
12
m
on
th
s.
i th
e
la
st
pa
tie
nt
en
te
re
d
th
e
ru
n-
in
in
20
12
bu
t
w
as
ra
nd
om
is
ed
in
20
13
.
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
820 J. J. V. McMurray et al.
Results
Between 8 December 2009 and 17 January 2013, 8442 patients
were randomized in PARADIGM-HF at 985 sites in 47 countries.
The clinical characteristics, baseline treatment, laboratory findings
and health-related quality of life are described in Tables 2–5. These
tables also show the same findings from SOLVD-T and more recent
trials in patients with HF-REF.11–25
Baseline characteristics
The average age of patients in PARADIGM-HF is 64 (SD 11) years,
similar to SOLVD-T and the other more recent trials with the
exception of EMPHASIS-HF (Eplerenone in Mild Patients Hospital-
ization And Survival study in Heart Failure) in which patients had a
higher average age; however, eligible participants in EMPHASIS-HF
had to be 55 years or older (Table 2). Consistent with previous tri-
als, the vast majority (78%) of patients are men. Similarly, as in most
trials, the majority of patients are in NYHA class II although this
proportion (70%) in PARADIGM-HF was greater than in SOLVD-T
(57%). The patients enrolled in PARADIGM-HF are more racially
diverse than most previous trials with the exception of HEAAL
(Heart failure Endpoint evaluation of Angiotensin II Antagonist
Losartan).11 Blood pressure is slightly lower in PARADIGM-HF
than in SOLVD-T and LVEF slightly higher, although the entry LVEF
threshold is higher in PARADIGM-HF (Tables 1 and 2). Heart rate
in PARADIGM-HF is similar to most other studies except SHIFT
(Systolic Heart Failure Treatment with the If Inhibitor Ivabradine
Trial, which mandated a heart rate of ≥70 bpm for inclusion) and
SOLVD-T.9,13
Medical and surgical history
More patients (71%) in PARADIGM-HF have a history of hyper-
tension than in SOLVD-T (42%) although the proportion in
PARADIGM-HF is consistent with most other contemporary tri-
als. Conversely, the proportion of patients in PARADIGM-HF
with an investigator-reported ischaemic aetiology is lower than
in SOLVD-T (and other trials), and this is in keeping the smaller
proportion in PARADIGM-HF with a history of myocardial infarc-
tion and previous coronary revascularization. The proportion of
patients with a diagnosis of diabetes is higher in recent trials (at
around one-third) compared with SOLVD-T (where about a quar-
ter of patients had diabetes). The proportion with atrial fibrillation
also seems higher although trials do not always distinguish between
atrial fibrillation at the time of enrolment and history of atrial
fibrillation.
Laboratory investigators
The proportion of patients with chronic kidney disease (esti-
mated glomerular filtration rate <60mL/min.1.73m2) is similar in
PARADIGM-HF and SOLVD-T, as well as in EMPHASIS-HF.14 ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. Baseline treatment
As expected, the biggest difference between PARADIGM-HF and
SOLVD-T is in treatment with a beta-blocker (93 vs. 8%), although
the use of this therapy in PARADIGM-HF reflects that in other
contemporary trials. Use of mineralocorticoid receptor antago-
nists (MRAs) is also likely to be quite different, although impossible
to quantify as MRA treatment was not recorded in SOLVD-T (as it
was not known to be beneficial at the time of that trial). The rate
of MRA use in PARADIGM-HF is, however, the joint highest in any
trial. Anticoagulant use is also more common in PARADIGM-HF
and other recent trials. Conversely, digoxin use is much less in
PARADIGM-HF (and other contemporary trials) than in SOLVD-T.
Device use in PARADIGM-HF is greater than in any other recent
pharmacological treatment trial but still low.
Signs and symptoms at baseline
With the exception of a third heart sound, the clinical findings
described in PARADIGM-HF are broadly consistent with SOLVD-T
and in the more recent trials that reported these (Table 3). Notably,
in these trials up to one in five patients had peripheral oedema and
around one in 10 had an elevated jugular venous pressure.
N-terminal pro B-type natriuretic
peptide
Relatively few trials have reported NT-proBNP levels. Those
that have are summarized in Table 4. The two trials with the
highest levels [CARE-HF (Cardiac Resynchronization in Heart
Failure), 1814 pg/mL, and COPERNICUS (Carvedilol Prospective
Randomized Cumulative Survival Trial), 1767 pg/mL] by design
enrolled more severely symptomatic patients with a particularly
low LVEF.15,20 Despite this, the median level in PARADIGM-HF
(1608 pg/mL) is only slightly less than in these two trials and higher
(or much higher) than in the other trials shown.
Health-related quality of life
Pharmacological therapy and device trials reporting KCCQOverall
Summary Score (OSS) are shown in Table 5 (where a lower score
reflects worse quality of life). The OSS in PARADIGM-HF is similar
to that in GISSI-HF and MADIT-CRT but higher (better) than in
several other recent trials.23,25
Discussion
The PARADIGM-HF trial is the largest, most contemporary and
most geographically diverse mortality–morbidity trial in patients
with HF-REF. It is testing the hypothesis that the ARNi LCZ696 is
superior to enalapril 10mg twice daily, the ACE inhibitor and dose
shown to reduce mortality and hospitalization for heart failure in
SOLVD-T.
Despite the 23 year gap between the start of recruitment to
SOLVD-T and the start of PARADIGM-HF, the baseline demo-
graphics of patients in both trials are remarkably similar with the
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Baseline characteristics and treatment in SOLVD-T, PARADIGM-HF and other recent heart failure and
reduced ejection fraction (HF-REF) trials
SOLVD-T,
N= 2569
CHARM-Added,
N= 2548
HEAALa,
N= 3834
RAFT,
N= 1798
SHIFT,
N= 6505
EMPHASIS-HF,
N= 2737
PARADIGM-HF,
N= 8442
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (mean) 61 64 66 66 60 69 64
Female sex (%) 20 21 30 17 23 22 22
NYHA class (%)
I 11 0 0 0 0 0 5
II 57 24 69 80 49 100 70
III 30 73 30 20 50 0 24
IV 2 3 1 0 2 0 1
Race (%)
White 80 92 61 – 89 83 66
Black 15 5 1 – – 2 5
Asian – – 22 – 8 12 18
Other 4 4 16 – 3 3 11
Heart rate (mean) bpm 80 74 72 – 80 72 72
Blood pressure (mean) mmHg
Systolic 125 125 125 – 122 124 121
Diastolic 77 75 72 – 76 75 74
LVEF (mean) % 25 28 33 23 29 26 29
QRS duration (mean) ms – – – 158 – 122 117
BMI (mean) kg/m2 – 28 27 – 28 28 28
Ischaemic aetiology (%) 71 62 – 67 67 69 60
Medical history (%)
Hospitalization for HF – 77 – 25c 100† 53 63k
Hypertension 42 48 60 45 67 66 71
Angina pectoris 37 53 65j – 43 27j
Myocardial infarction 66 56 – 56 50 43
PCI N/A 15 – 24 – 22 21
CABG 29* 25 – 34 – 19 15
Atrial fibrillation/flutter 10 26 28 13e 8d 31 37i
LBBBb – 31 – 72 – 27 20
Diabetes mellitus 26 30 31 34 31 31 34
Stroke (8)** 9 – – 8 10 9
Current smoker 22 17 – 14 18 – 14
Renal function
Serum creatinine 106 103 97 – – 102 99
(μmol/L) 76*** 71 – 61 75 71 68
eGFR mL/min.1.73m2 (mean) 36*** 33 – 50 – 33 37
eGFR <60 mL/min.1.73m2 (%)
Treatment (%)
Diuretic 85 90 77 85 – 85 80
ACE inhibitor N/A 100 N/A – 79 78 N/Am
ARB N/A N/A N/A – 14 19 N/Am
ACEi, ARB, or both N/A N/A N/A 97 – 94 N/Am
𝛽eta-blocker 8 55 72 90 90 87 93
MRA – 17 38 42f 60 N/A 60
Digoxin 67 58 42 35 22 27 30n
Anticoagulant 16 38 33 34g – – 32o
Antiplatelet
Aspirin – 51 51 67 – – 52p
ADP antagonist N/A – – 16 – – 15q
Any antiplatelet 33 – – – – – 57
Lipid lowering – 41 39h 68h 58h 62 56
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Table 2 Continued
SOLVD-T,
N= 2569
CHARM-Added,
N= 2548
HEAALa,
N= 3834
RAFT,
N=1798
SHIFT,
N= 6505
EMPHASIS-HF,
N= 2737
PARADIGM-HF,
N= 8442
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CRT N/A N/A – N/A 1 2 7l
ICD N/A 4 – 100 4 13 15
CRT-D N/A N/A – N/A – 6 5
SOLVD-T, Studies of Left Ventricular Dysfunction Treatment trial; CHARM-Added, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity
(CHARM)-Added trial; HEAAL, Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan; RAFT, Resynchronization/Defibrillation for Ambulatory Heart Failure
Trial; SHIFT, Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial; EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization And Survival study in Heart
Failure; PARADIGM-HF, Prospective comparison of ARNi (angiotensin receptor neprilysin inhibitor) with ACEi (angiotensin-converting enzyme inhibitor) to Determine
Impact on Global Mortality and morbidity in Heart Failure trial; N/A, not applicable; −, not reported; BMI, body mass index; PCI, percutaneous coronary intervention; CABG,
coronary artery bypass grafting; LBBB, left bundle branch block; ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid
receptor antagonist; ADP, adenosine diphosphate; CRT, cardiac resynchronisation therapy; ICD, implantable cardioverter defibrillator; CRT-D, cardiac resynchronization
therapy—defibrillator.
aMedian.
bNYHA class at randomization—all patients were in NYHA functional class II or greater at entry to the active run-in period.
cin previous 6months.
dcurrent AF excluded.
epermanent AF at baseline.
fspironolactone.
gwarfarin.
hstatin.
ihistory of AF only.
jhistory of ischaemic heart disease in HEAAL and of stable or unstable angina in PARADIGM-HF.
kno time limit.
lCRT-D or CRT-P.
mpre-enrolment, 77% were treated with an ACE inhibitor and 22% with an ARB (100%) with one, other or both).
nincludes all digitalis derivatives.
oincludes vitamin K antagonists, rivaroxiban, dabigatran, and apixaban.
pincludes all aspirin derivatives, alone or in combinations.
qincludes clopidogrel, prasugrel, ticagrelor, ticlopidine, and their combinations.
*CABG or PCI.
**Cerebrovascular disease.
***Creatinine clearance (in SOLVD overall, the mean eGFR was 70mL/min.1.73m2 and 32% of patients had an eGFR <60mL/min.1.73m2).
†Per protocol, all patients had an admission for worsening heart failure within 12months.
exception of race because of the much wider geographical reach
of PARADIGM-HF.7,10
However, NYHA class distribution was somewhat more
favourable, and mean LVEF higher in PARADIGM-HF than
in SOLVD-T, possibly reflecting greater treatment with
disease-modifying drugs (and devices) in the former. The lower
heart rate and systolic blood pressure in PARADIGM-HF probably
also result from this. In particular, the higher heart rate in
SOLVD-T presumably reflects the conduct of the trial before the
value of beta-blockers in heart failure was recognized (see below).
The proportion of patients with diabetes is higher in contem-
porary trials, including PARADIGM-HF, compared with SOLVD-T
and this may in part reflect newer and lower diagnostic thresholds
for diabetes since the start of enrolment in SOLVD-T.26 Patients in
contemporary trials may also be more obese than in the past but
this hypothesis could not be tested as body mass index was not
recorded in SOLVD-T.
A more puzzling difference is in the lower proportion of patients
with coronary heart disease in PARADIGM-HF. Whether this
reflects greater diagnostic accuracy in more contemporary prac-
tice, the different racial and geographical mix of patients in the two
trials or some other factor is uncertain.
As expected, background therapy in PARADIGM-HF is quite
different than in SOLVD-T, with greater use of beta-blockers and .
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
. MRAs, oral anticoagulants (and presumably statins, which were not
available during SOLVD-T), in keeping with the accrual of new
evidence of treatment effectiveness and evolution of guidelines
to reflect this.27,28 Even among contemporary trials, the patients
in PARADIGM-HF are particularly well treated, with the highest
rate of use of beta-blockers (93%) and the joint highest rate
(60%) of MRA use along with SHIFT (60%), even though SHIFT
had a higher proportion of NYHA class III/IV patients (52%) than
PARADIGM-HF (25%). Consequently, PARADIGM-HF will test the
value of LCZ696 in addition to the best pharmacological standard
of care. The lower use of digoxin in PARADIGM-HF, compared
with SOLVD-T presumably reflects changed perceptions of the
value of this agent and newer alternative therapies of proven
effectiveness.29
Despite strong evidence of effectiveness, device use remains
low in contemporary trials, especially those with a large propor-
tion of patients enrolled in regions other than North America
and Western Europe, where there is greater uptake of cardiac
resynchronization therapy (CRT) and, in particular, implantable car-
dioverter defibrillators (ICDs).13,14,17,27,28 In this respect, patients
in PARADIGM-HF had similar rates of device use as those in
EMPHASIS-HF and more than in SHIFT.13,14
Although the majority of patients in PARADIGM-HF were in
NYHA functional class II or III at the time of randomization, the
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Baseline signs of heart failure in PARADIGM-HF compared with other trials in heart failure and reduced
ejection fraction
SOLVD-T9,
N= 2569
CARE-HF15,
N= 813
COMET16,
N= 1511
CHARM-Added10,
N= 2548
MERIT-HF18,
N= 3991
PARADIGM-HF7,
N= 8442
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mean age (year) 61 67 62 64 64 64
NYHA class distribution (%)
I/II 68 21 48 24 41 75
IIII 30 64 48 73 56 24
IIV 2 10 3 3 3 1
LVEF (%) 25 25* 26 28 28 29
Proportion (%) with
Rales 12 12 9 15 11 8
S3 23 20 19 18 23 9
JVP elevation 11 18 N/R 11 14 10
Peripheral oedema 17 18 13 23 15 21
SOLVD-T, Studies of Left Ventricular Dysfunction Treatment trial; CARE-HF, Cardiac Resynchronization in Heart Failure; COMET, Carvedilol Or Metoprolol European Trial;
CHARM-Added, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial; MERIT-HF, the Metoprolol CR/XL Randomized
Intervention Trial in Congestive Heart Failure; PARADIGM-HF, Prospective comparison of ARNi with ACEI to Determine Impact on Global Mortality and morbidity in Heart
Failure trial; NYHA, New York Heart Association; S3, third heart sound; JVP, jugular venous pressure; N/R, not reported.
*Median.
Table 4 Plasma N-terminal pro 𝜷-type natriuretic peptide (NT-proBNP) concentrations in PARADIGM-HF compared
with other trials in heart failure and reduced ejection fraction (HF-REF)
CARE-HF15,
N= 813
COMET16,
N= 1511
CORONA19,
N= 5011
COPERNICUS20,
N= 2289
Val-HeFT21,
N= 5010
PARADIGM-HF7,
N= 8442
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mean age (years) 67 62 73 63 63 64
NYHA class distribution (%)
I/II 21 48 37 0 61 75
III 64 48 62 0 36 24
IV 10 3 2 100** 2 1
Mean LVEF (%) 25* 26 31 20 27 29
AF (%) 0 20† 24† N/R 12† 24†
NT proBNP, pg/mL* 1814 1242 1497 1767 861 1608
CARE-HF, Cardiac Resynchronization in Heart Failure; COMET, Carvedilol Or Metoprolol European Trial; CORONA, Controlled Rosuvastatin Multinational Trial in Heart
Failure; COPERNICUS, Carvedilol Prospective Randomized Cumulative Survival Trial; Val-HeFT, Valsartan Heart Failure Trial. PARADIGM-HF, Prospective comparison of
ARNi with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction;
AF, atrial fibrillation.
NT proBNP was measured in 732 patients in CARE-HF, 1559 patients in COMET, 3664 patients in CORONA, 1011 patients in COPERNICUS, 1742 patients in the placebo
group of Val-HeFT, and 8394 patients in PARADIGM-HF.
NT proBNP was measured in 732 patients in CARE-HF, 1559 patients in COMET, 3664 patients in CORONA, 1011 patients in COPERNICUS, 1742 patients in the placebo
group of Val-HeFT, and 8394 patients in PARADIGM-HF. Patient Characteristics are taken from overall trial population.
*Median.
**NYHA class not reported but all patients said to have ‘severe’ heart failure with symptoms at rest or on minimal exertion.
†On baseline electrocardiogram.
median NT-proBNP concentration was almost as high as in the
CARE-HF and COPERNICUS trials, which enrolled patients with
more severe functional limitation and a very low LVEF.15,20 This
probably reflects two factors. First, in PARADIGM-HF, patients
without a history of hospitalization owing to heart failure within
12months were required to have either a BNP ≥150 pg/mL or
NT-proBNP of ≥600 pg/mL in order to be enrolled.7 Second, the
proportion of patients with atrial fibrillation or flutter at baseline
was higher in PARADIGM-HF than in any other trial in which
NT-proBNP was measured (Table 4). It is anticipated that the high ..
..
..
..
..
..
..
..
..
..
..
..
..
..
. median NT-proBNP level in PARADIGM-HF will help ensure that
the expected rates for CV mortality and hospitalization owing to
heart failure will be obtained.7
In addition to the primary endpoints of CV death and hos-
pital admission for treatment of worsening heart failure, the
first secondary endpoint in PARADIGM-HF is health-related
quality of life (HRQL), as assessed by the KCCQ.30 The HRQL
in patients with heart failure is associated with many factors,
including NYHA class (patients with worse functional class
tend to have worse HRQL), age (younger patients on average
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Table 5 Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score (OSS) in heart failure and
reduced ejection fraction trials—a higher score means better quality of life
RED-HF22,
N= 2278
SHIFT13,
N= 6558
GISSI-HF23,
N= 4574
HF-ACTION24,
N= 2331
MADIT-CRT25,
N=1820
PARADIGM-HF7,
N= 8442
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mean age (years) 70 60 68 59* 64 64
Female sex (%) 41 23 23 28 25 22
NYHA class
I/II 35 49 62 63 100** 75
III 63 50 35 36 0 24
IV 2 2 3 1 0 1
LVEF 30 29 33 25* 24 29
Other variables Anaemia Recent HF
hospital-
ization
HF hospi-
talization
past year
Suitable for
exercise
training
QRSd
≥130ms
Elevated BNP/NT
proBNP± recent
HF hospitalization
Intervention OMT vs.
OMT+
darbepoetin
OMT vs
OMT+
ivabradine
OMT vs.
OMT+
rosuvastatin†
OMT vs.
OMT+
exercise
training
OMT+CRT-D
vs.
OMT+ ICD
OMT+ enalapril vs.
OMT+ LCZ696
KCCQ OSS 56 65 73 66 76 73
RED-HF, Reduction of Events With Darbepoetin Alfa in Heart Failure Trial; SHIFT, Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial; GISSI-HF, Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico-heart failure; HF-ACTION, Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training;
MADIT-CRT, Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy; PARADIGM-HF, Prospective comparison of ARNI with ACEI
to Determine Impact on Global Mortality and morbidity in Heart Failure trial. NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; OMT, optimum
medical treatment.
*Median.
**NYHA class II 15%.
†OMT vs. OMT+ omega-3 polyunsaturated fatty acids; 10% of patients had a LVEF >40%; KCCQ was recorded in 1699 patients in MADIT-CRT, 1465 in GISSI-HF, 2330 in
HF-ACTION, 1944 in SHIFT, 2210 in RED-HF and 496 in STICH. The mean age, NYHA class distribution and LVEF are those reported in the main trial.
report worse HRQL than older ones), sex (women report
worse HRQL than men), and comorbidity.31 Differences among
trials in these factors may explain why, for example, RED-HF
(Reduction of Events With Darbepoetin Alfa in Heart Failure
Trial, which had a high proportion of women and in which
all patients had anaemia) reported the worst HRQL, and why
patients in both SHIFT (high proportion of patients in NYHA
class III and IV) and HF-ACTION (Heart Failure: A Controlled
Trial Investigating Outcomes of Exercise Training; youngest
average age) had generally worse HRQL than those in other
contemporary trials, including PARADIGM-HF.7,15,22,24 Patients
in PARADIGM-HF had a KCCQ OSS similar to that of patients
in GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto miocardico-heart failure) and MADIT-CRT (Multi-
center Automatic Defibrillator Implantation Trial With Cardiac
Resynchronization Therapy), probably reflecting the larger pro-
portion of patients in NYHA class I or II in these trials, as well as
age and gender distribution.23,25
As with all analyses of this type, there are limitations, the prin-
cipal one of which is that the explanations for many of the differ-
ences observed are speculative and cannot be proven. However,
this report does provide a quarter-century perspective on the
evolution of trials in HF-REF and, in particular changes in therapy
over time.
In summary, our findings show that while the basic demo-
graphics of the selected patients with HF-REF enrolled in ..
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. PARADIGM-HF differ little from those in SOLVD-T, the poten-
tial benefit of LCZ696 over enalapril is being tested in addition
to two additional disease-modifying drugs in the majority of
patients in PARADIGM-HF. Despite these treatments, patients
in PARADIGM-HF have persisting symptoms and signs, reduced
HRQL, a chronically low LVEF and elevated levels of B-type natri-
uretic peptides. PARADIGM-HF will test whether further augmen-
tation of the endogenous protective natriuretic peptide and other
vasoactive systems will reduce morbidity and mortality in HF-REF.
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